raisch jennifer

Ms. raisch jennifer

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
RJraisch jennifer
raisch jennifer
ACAnthony Cote-biron
Anthony Cote-biron
NRNathalie Rivard
Nathalie Rivard
The WNT/β-catenin signaling pathway controls stem and progenitor cell proliferation, survival and differentiation in epithelial tissues. Aberrant stimulation of this pathway is therefore frequently observed in cancers from epithelial origin. For instance, colorectal and hepatic cancers display activating mutations in the CTNNB1 gene encoding β-catenin, or inactivating APC and AXIN gene mutations. However, these mutations are uncommon in breast and pancreatic cancers despite nuclear β-catenin localization, indicative of pathway activation. Notably, the low-density lipoprotein receptor-related protein 6 (LRP6), an indispensable co-receptor for WNT, is frequently overexpressed in colorectal, liver, breast and pancreatic adenocarcinomas in association with increased WNT/β -catenin signaling. Moreover, LRP6 is hyperphosphorylated in KRAS-mutated cells and in patient-derived colorectal tumours. Polymorphisms in the LRP6 gene are also associated with different susceptibility to developing specific types of lung, bladder and colorectal cancers. Additionally, recent observations suggest that LRP6 dysfunction may be involved in carcinogenesis. Indeed, reducing LRP6 expression and/or activity inhibits cancer cell proliferation and delays tumour growth in vivo. This review summarizes current knowledge regarding the biological function and regulation of LRP6 in the development of epithelial cancers—especially colorectal, liver, breast and pancreatic cancers.

15 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
RJraisch jennifer
raisch jennifer
ACAnthony Cote-biron
Anthony Cote-biron
MLMarie-Josée Langlois
Marie-Josée Langlois
CLCaroline Leblanc
Caroline Leblanc
NRNathalie Rivard
Nathalie Rivard
Intestinal epithelial self-renewal is tightly regulated by signaling pathways controlling stem cell proliferation, determination and differentiation. In particular, Wnt/β-catenin signaling controls intestinal crypt cell division, survival and maintenance of the stem cell niche. Most colorectal cancers are initiated by mutations activating the Wnt/β-catenin pathway. Wnt signals are transduced through Frizzled receptors and LRP5/LRP6 coreceptors to downregulate GSK3β activity, resulting in increased nuclear β-catenin. Herein, we explored if LRP6 expression is required for maintenance of intestinal homeostasis, regeneration and oncogenesis. Mice with an intestinal epithelial cell-specific deletion of Lrp6 (Lrp6IEC-KO) were generated and their phenotype analyzed. No difference in intestinal architecture nor in proliferative and stem cell numbers was found in Lrp6IEC-KO mice in comparison to controls. Nevertheless, using ex vivo intestinal organoid cultures, we found that LRP6 expression was critical for crypt cell proliferation and stem cell maintenance. When exposed to dextran sodium sulfate, Lrp6IEC-KO mice developed more severe colitis than control mice. However, loss of LRP6 did not affect tumorigenesis in ApcMin/+ mice nor growth of human colorectal cancer cells. By contrast, Lrp6 silencing diminished anchorage-independent growth of BRafV600E-transformed intestinal epithelial cells (IEC). Thus, LRP6 controls intestinal stem cell functionality and is necessary for BRAF-induced IEC oncogenesis.

18 December 2025 in BJUI Compass
Verified
Journal Article
Open access
AMAlexandrine Martel
Alexandrine Martel
LRLucas Raue
Lucas Raue
PAPatrice Hodonou Avogbe
Patrice Hodonou Avogbe
RJraisch jennifer
raisch jennifer
CJClaudio Jeldres
Claudio Jeldres
Francois-Michel BoisvertFrancois-Michel Boisvert
Francois-Michel Boisvert
Background and Objective: Bladder cancer (BC), a prevalent malignancy, poses significant diagnostic and surveillance challenges due to its high recurrence rates and reliance on cystoscopy, an invasive procedure for diagnosis and monitoring. While urine‐based genomic and proteomic biomarkers offer promising non‐invasive alternatives, their clinical implementation remains limited. This review synthesizes evidence from multicentric studies on urinary biomarkers for BC and evaluates their potential in reducing unnecessary invasive cystoscopies. Methods: A comprehensive review of literature was conducted searching for multicentric studies on urine‐based genomic and proteomic biomarkers for BC detection and/or surveillance. MEDLINE/Pubmed, Embase and Scopus databases and BJUI, UroToday and European Urology Oncology registries were searched using National Library of Medicine Medical Subject Headings (MeSH) terms. Emphasis was placed on the comparative performance of diagnostic platforms across different research and clinical settings. Key Findings and Limitations: The literature search yielded 51 reports that were included for analysis. Multicentre studies enhance the generalizability of findings by addressing inter‐laboratory variability and population diversity. This review underscores the importance of standardization, comparative performance analyses that these studies provide, and the potential for cost‐effective non‐invasive diagnostic tools. However, despite FDA approvals, no biomarker has replaced cystoscopy in clinical settings due to an inconsistent and insufficient combination of sensitivity, specificity and cost‐effectiveness parameters. The performance of AssureMDX and Enhanced CxBladder tests showed the most promise, but further large‐scale, standardized validation is still necessary. Conclusions and Clinical Implications: Urine‐based biomarkers have the potential to improve early BC detection and surveillance while reducing reliance on invasive procedures and costs related to the disease. Future efforts should prioritize cost‐effective, large‐scale multicentric studies to facilitate the adoption of these biomarkers into routine practice.

1 December 2025 in JU Open Plus
Verified
Journal Article
Open access
SBSabrina Bouchard
Sabrina Bouchard
DLDominique Lévesque
Dominique Lévesque
RJraisch jennifer
raisch jennifer
MBMartin Bisaillon
Martin Bisaillon
CJClaudio Jeldres
Claudio Jeldres
Francois-Michel BoisvertFrancois-Michel Boisvert
Francois-Michel Boisvert
Purpose: Bladder cancer is the ninth most common malignancy worldwide and poses a significant diagnostic challenge due to high recurrence rates and dependence on invasive procedures such as cystoscopy. Urine cytology, a commonly used noninvasive test, suffers from low sensitivity, particularly for high-grade tumors. This study aimed to identify a panel of urinary protein biomarkers capable of reliably detecting high-grade bladder cancer through a noninvasive approach. Methods: Urinary samples from patients with confirmed bladder cancer and from control individuals were analyzed using mass spectrometry-based proteomics. Differential protein expression was assessed to identify potential diagnostic markers. Candidate proteins were selected based on consistent overexpression in cancer samples and validated using statistical modeling. Results: A combination of 4 proteins—Complement Factor H, Fibrinogen β, Alpha-2-macroglobulin, and Pancreatic Alpha-amylase—showed strong diagnostic potential. This panel achieved 100% sensitivity for high-grade tumor detection, with a false-positive rate below 20%, depending on patient history. The biomarker panel outperformed traditional cytology, particularly for early-stage tumors. Limitations include sample size and the need for external validation in larger, multicenter cohorts. Conclusions: The identified urinary protein panel offers a promising noninvasive alternative for the detection of high-grade bladder cancer. This approach could significantly improve early diagnosis, reduce reliance on invasive procedures, and enhance patient follow-up. Future validation studies may support its integration into clinical practice as a cost-effective diagnostic tool.

22 December 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
AAAlain B. Alfonso
Alain B. Alfonso
VPVéronique Pomerleau
Véronique Pomerleau
VNVilcy Reyes Nicolás
Vilcy Reyes Nicolás
RJraisch jennifer
raisch jennifer
CJCarla-Marie Jurkovic
Carla-Marie Jurkovic
NPNathalie Perreault
Nathalie Perreault
FoxL1+telocytes (TCFoxL1+) are novel gastrointestinal subepithelial cells that form a communication axis between the mesenchyme and epithelium. TCFoxL1+ are strategically positioned to be key contributors to the microenvironment through production and secretion of growth factors and extracellular matrix (ECM) proteins. In recent years, the alteration of the bone morphogenetic protein (BMP) signaling in TCFoxL1+ was demonstrated to trigger a toxic microenvironment with ECM remodeling that leads to the development of pre-neoplastic gastric lesions. However, a comprehensive analysis of variations in the ECM composition and its associated proteins in gastric neoplasia linked to TCFoxL1+ dysregulation has never been performed. This study provides a better understanding of how TCFoxL1+ defective BMP signaling participates in the gastric pre-neoplastic microenvironment. Using a proteomic approach, we determined the changes in the complete matrisome of BmpR1a△FoxL1+ and control mice, both in total antrum as well as in isolated mesenchyme-enriched antrum fractions. Comparative proteomic analysis revealed that the deconstruction of the gastric antrum led to a more comprehensive analysis of the ECM fraction of gastric tissues microenvironment. These results show that TCFoxL1+ are key members of the mesenchymal cell population and actively participate in the establishment of the matrisomic fraction of the microenvironment, thus influencing epithelial cell behavior.

1 January 2025 in Biochemistry and Cell Biology
Verified
Journal Article
Open access
AMAnna Meller
Anna Meller
RJraisch jennifer
raisch jennifer
DLDominique Lévesque
Dominique Lévesque
EFEtienne Fafard-Couture
Etienne Fafard-Couture
MSMichelle Scott
Michelle Scott
Francois-Michel BoisvertFrancois-Michel Boisvert
Francois-Michel Boisvert
Pseudogenes, traditionally considered non-functional gene copies, have garnered attention due to emerging evidence of their transcription and translation. Ubiquitin is canonically expressed from UBA52 and RPS27A genes as fusion proteins, with additional polyubiquitin precursors encoded by UBB and UBC. Several pseudogenes of these loci are annotated as non-functional. Here, we report that the RPS27A pseudogene, RPS27AP5, expresses two proteins: a ubiquitin variant (UbP5) and a ribosomal protein variant (S27aP5). These proteins mature through cleavage and exhibit localization and biochemical characteristics similar to their parental counterparts. S27aP5 integrates into ribosomes, and its overexpression leads to an increased 80S monosome fraction. Using affinity purification and polysome profiling, we show that S27aP5-containing ribosomes exhibit altered mRNA associations. The findings suggest that RPS27A, a processed pseudogene, can give rise to a ribosomal protein variant capable of integrating into monosomes and influencing mRNA association aligns with growing evidence that ribosomes may exhibit functional diversity.